State of the evidence: Evidence level: small uncontrolled pilot involving different tumors. It cannot establish that MCP caused changes in quality of life or disease control.
The outline of the pilot
The 2007 study enrolled 49 people with different advanced solid tumors. Six of the 29 completing two cycles met a composite clinical-benefit measure; 11 of 49 had stable disease after two cycles. There was no control group.[1] These observations cannot establish that MCP caused the reported changes.
Separate wellbeing from tumor response
Less pain or improved ability to manage everyday activities is a valuable observation. It does not automatically show that a tumor has shrunk. Conversely, a change on imaging cannot fully describe how someone feels. Careful interpretation does not set these outcomes against one another; it asks that both be measured appropriately and reported according to their distinct meanings.
Understanding a composite benefit measure
Researchers sometimes combine several domains into one outcome definition. Readers need to know which conditions count and how they contribute. Changes in pain, function or weight may influence the combined result differently. Rather than accepting the phrase clinical benefit at face value, look for the components that changed and the definition established before the analysis. A broad label can conceal several different experiences.
The limits of stable disease
Stable disease can describe a situation that meets neither progression nor response criteria during an assessment period. The term alone does not prove that a product stopped cancer. Such a causal interpretation depends on comparison and follow-up conditions. Changing the phrase into a headline claiming that cancer was halted gives the observation a stronger meaning than the research design can support.
Different cancers within one group
Cancer types differ in their course and previous treatment histories. Combining them in a small study means an overall proportion may not provide a reliable expectation for one particular tumor type. Before applying a finding to an individual situation, examine the cancer, prior therapies and assessment period. The total number enrolled does not establish that each subgroup contains enough information for its own conclusion.
Incomplete follow-up and the next research question
When only part of the original group completes an assessment period, the findings represent a narrower population. The circumstances of withdrawal and handling of missing data should therefore be visible. Stronger research would specify the comparison group and patient-important outcomes from the beginning. A pilot can help shape that study, but does not independently establish a recommendation about supportive care or cancer treatment.
References
This article provides general health information. Research findings about MCP are not individual recommendations for diagnosing or treating disease. Medicine and supplement use should be discussed with a doctor or pharmacist.
Published and sources assessed: 17 October 2026